Red flags / Delisting notice
Passage Bio receives Nasdaq notice for stockholders' equity deficiency, plans merger with Remix to cure
On November 12, 2026, Nasdaq notified Passage Bio that it was not in compliance with Listing Rule 5550(b)(1), which requires at least $2,500,000 in stockholders' equity, after the company reported equity of $50,000 in its Form 10-Q for the quarter ended September 30, 2026. The company says its pending mergers with Remix Therapeutics are expected to close and restore compliance, and the letter has no immediate effect on the stock's listing; if the mergers are not completed within the Nasdaq period, the company intends to submit a compliance plan. A listing deficiency of this kind raises the risk of delisting if the merger is delayed, which matters for holders relying on the current listing.
“In its Quarterly Report on Form 10-Q for the quarter ended September 30, 2026, Passage Bio reported stockholders' equity of $50,000, and, as of November 12, 2026, Passage Bio did not meet the alternatives of market value of listed securities or net income from continuing operations.”
What the stock did
From the last close before the filing was public. Market cap now: $13M.
8-K Item 3.01: the exchange says the stock no longer meets a listing rule. Flags are a screen for filings worth reading, not advice. Read the filing before acting on it.
Other flags on PASG
| Filed | Stock | Flag | What the filing says | Mkt cap | 5 days | 20 days |
|---|---|---|---|---|---|---|
| Nov 10, 7:16 AM ET | PASG Passage Bio Inc. | Going concern ElevatedForm 10-Q | Passage Bio flags substantial doubt about going concern as cash may not cover next twelve months | $13M | +20.4% | - |